heart attack patients

Elevated Death Risk After Heart Attack

admin — Tue, 04 Nov 2008 16:30:38 -0600

Heart attack patients face the highest risk of dying from sudden cardiac death within the first month after cardiac arrest, according to the Journal of the American Medical Association.

Depression, health care services and heart attacks -- what's the...

admin — Tue, 21 Oct 2008 00:00:00 -0500

(Centre for Addiction and Mental Health) Data from almost 2000 heart attack patients showed that depression symptoms alone resulted in an increase in health service consumption. The data also showed that depression caused the greatest increase in health service use in those patients with lower cardiac illness severity. This is one of the first studies to quantify the relationship between depression symptoms, cardiac illness severity and their effect on health service consumption.

HORIZONS AMI will help set guidelines for drug and stent therapy

admin — Wed, 15 Oct 2008 00:00:00 -0500

(Cardiovascular Research Foundation) The HORIZONS AMI clinical trial measuring the safety and efficacy of the use of the medication bivalirudin compared to standard drug therapy -- heparin and glycoprotein IIb/IIIa inhibitors -- in heart attack patients who receive angioplasty, found that after 1 year, use of bivalirudin resulted in significantly lower rates of all-cause death, death from cardiac causes, and major bleeding.

Drug-eluting stents more effective, equally as safe as bare meta...

admin — Wed, 15 Oct 2008 00:00:00 -0500

(Cardiovascular Research Foundation) Late-breaking data from the HORIZONS AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction) trial reveal that after one year, use of a drug-eluting (paclitaxel) stent demonstrated significantly reduced rates of target lesion revascularization and binary angiographic restenosis when compared to the use of a bare metal stent in heart attack patients.

Heart Attack? Drug-Coated Stents Best

admin — Thu, 25 Sep 2008 12:45:47 -0500

Drug-coated stents safe for treating all heart attack patients -- and may actually reduce deaths more than bare stents, Brigham & Women's researchers find.

Study into near-death experiences

admin — Thu, 18 Sep 2008 01:00:51 -0500

A large study is to examine whether heart attack patients really do have near-death "out of body" experiences.

Heart attack patients who stop statin risk death, say McGill res...

admin — Wed, 27 Aug 2008 00:00:00 -0500

(McGill University) Patients discontinuing statin medication following an acute myocardial infarction increase their risk of dying over the next year, say researchers at McGill University and the McGill University Health Center. Their study was published in a recent issue of the European Heart Journal.

Novel approach may protect against heart attack injury

admin — Thu, 10 Jul 2008 00:00:00 -0500

(Children's Hospital of Philadelphia) Researchers at The Children's Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies. The finding has the potential to become an emergency treatment for heart attack patients, particularly since already existing drugs might be pressed into service to produce the protective effects.

Findings released from 1 of the largest percutaneous coronary in...

admin — Fri, 23 May 2008 00:00:00 -0500

(Columbia University Medical Center) A study led by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, has shown that heart attack patients who were administered the direct thrombin inhibitor bivalirudin during primary angioplasty had a reduced rate of adverse clinical events, a lower rate of major bleeding, and a lower mortality rate than those who were treated with a regimen of heparin and glycoprotein IIb/IIIa inhibitors.

Landmark study reveals superiority of bivalirudin in heart attac...

admin — Wed, 21 May 2008 00:00:00 -0500

(Cardiovascular Research Foundation) The New England Journal of Medicine published results of the HORIZONS AMI trial which showed the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduced net adverse clinical events by 24 percent compared to the standard treatment, as well as reduced the risk of overall mortality by 33 percent and cardiac mortality by 38 percent.